. * * window.aa needs to exist and be usable by ANY module's script, * however early it runs - main-nav's script, for one, runs near * the top of

91探花

, well before the real search-insights.js * so the download * begins as early as before. Repeat calls share the same downloads, a * failed load is retried on the next call, and the versions / SRI * hashes live only here. * * Algolia Insights is unaffected: window.aa above is still created in * on every page and queues events until search-insights loads. * * window.loadAlgoliaLibs({ priority: 'high' }) (Oct 2026): used by the * /search page, where the first results wait on these libraries. Chrome * gives async scripts low priority, behind images and fonts; this asks * for high instead (fetchpriority). Only the first call for a library * sets its priority - later calls share that download. */ (function (win, doc) { var LIBS = [ { ready: function () { return !!win['algoliasearch/lite']; }, src: 'https://cdn.jsdelivr.net/npm/algoliasearch@5.52.1/dist/lite/builds/browser.umd.js', integrity: 'sha256-I2oYUIvhx1g6l4lTP+yoERbzLIHKzw4AKaBRQPwIeDY=' }, { ready: function () { return !!win.instantsearch; }, src: 'https://cdn.jsdelivr.net/npm/instantsearch.js@4.98.0/dist/instantsearch.production.min.js', integrity: 'sha256-ngmqZk4WBxUw257aMYZayyNBd983INngagv0jI6Ecfs=' } ]; function loadOne(lib, options) { if (lib.ready()) return Promise.resolve(); // One download per library, shared by every caller; reset on // failure so the next call retries just the library that failed. if (lib.pending) return lib.pending; lib.pending = new Promise(function (resolve, reject) { var script = doc.createElement('script'); script.src = lib.src; script.integrity = lib.integrity; script.crossOrigin = 'anonymous'; script.async = true; if (options && options.priority === 'high') script.setAttribute('fetchpriority', 'high'); script.onload = function () { lib.ready() ? resolve() : reject(new Error('Loaded but not available: ' + lib.src)); }; script.onerror = function () { script.remove(); reject(new Error('Could not load ' + lib.src)); }; doc.head.appendChild(script); }); lib.pending.catch(function () { lib.pending = null; }); return lib.pending; } win.loadAlgoliaLibs = function (options) { return Promise.all(LIBS.map(function (lib) { return loadOne(lib, options); })); }; })(window, document); . */ window.hsConversationsSettings = window.hsConversationsSettings || {}; window.hsConversationsSettings.loadImmediately = false; (function (win) { var EVENTS = ['pointerdown', 'keydown', 'touchstart', 'scroll', 'mousemove', 'wheel']; var done = false; /* 19 Oct 2026 - chat widget layout shift (field CLS). Phones fail Core Web Vitals on CLS (p75 ~0.2 site-wide in CrUX for months). Biggest cause found: HubSpot's chat container is fixed to the bottom-right corner and changes size - 100x96 launcher to 282x253 when the welcome message pops up (~5 s after load), and to full screen when a visitor opens the chat. Its top-left corner moves, so Chrome scores it as a layout shift: 0.088 per page view at 360x640 (0.044 at 412x850), on every page. Taps happen inside the chat iframe, so the parent page never sees the input and the open/close shifts count too. Fix: whenever the container's size changes it is made transparent for 400 ms (Chrome doesn't score shifts of invisible elements), then shown again at its new size. Tested on live io1001 at 360x640 in a cookie-less frame: the 0.088 shift no longer appears. The chat itself is unchanged - it just appears 0.4 s later at each resize. Relies on HubSpot's container id; if that changes this does nothing (no error). */ function cloakChatResizes() { var ID = 'hubspot-messages-iframe-container'; function watch(c) { if (c.getAttribute('data-bb-cloak')) return; c.setAttribute('data-bb-cloak', '1'); var last = c.offsetWidth + 'x' + c.offsetHeight, timer = null; new MutationObserver(function () { var size = c.offsetWidth + 'x' + c.offsetHeight; if (size === last) return; last = size; c.style.setProperty('opacity', '0', 'important'); clearTimeout(timer); timer = setTimeout(function () { c.style.removeProperty('opacity'); }, 400); }).observe(c, { attributes: true, attributeFilter: ['style', 'class'], subtree: true, childList: true }); } var found = document.getElementById(ID); if (found) { watch(found); return; } if (!document.body || !('MutationObserver' in win)) return; var mo = new MutationObserver(function () { var c = document.getElementById(ID); if (c) { mo.disconnect(); watch(c); } }); mo.observe(document.body, { childList: true }); setTimeout(function () { mo.disconnect(); }, 30000); } function loadWidget() { var api = win.HubSpotConversations; if (api && api.widget && api.widget.status && api.widget.status().loaded) return; try { cloakChatResizes(); } catch (e) {} if (api && api.widget) api.widget.load(); } function onFirstInteraction() { if (done) return; done = true; EVENTS.forEach(function (type) { win.removeEventListener(type, onFirstInteraction, { passive: true }); }); var start = function () { if (win.HubSpotConversations) loadWidget(); else (win.hsConversationsOnReady = win.hsConversationsOnReady || []).push(loadWidget); }; if ('requestIdleCallback' in win) win.requestIdleCallback(start, { timeout: 1500 }); else setTimeout(start, 200); } EVENTS.forEach(function (type) { win.addEventListener(type, onFirstInteraction, { passive: true }); }); })(window);

91探花

Skip to main content
Home
91探花
Alzheimer's disease models

Human iPSC-derived Alzheimer's disease models

Buy products to model Alzheimer's disease Browse resources

Consistent, defined and scalable human iPSC-derived disease models for Alzheimer's disease research and drug discovery

Powered by opti-ox鈩� 

Alzheimer's disease, the most common type of dementia, is a neurodegenerative disorder that progressively undermines patients' cognitive abilities, impairing their capacity to create and retrieve memories. Studying Alzheimer鈥檚 disease remains a significant challenge, in part because of difficulties accurately emulating the disease's pathophysiology in vitro.

There is a pressing need for an in vitro model of Alzheimer's disease that can be used to accurately and reliably study the effect of disease-associated mutations, disease progression and to identify potential therapeutic targets. ioDisease Model Cells provide scientists with defined, consistent and scalable human iPSC-derived cells engineered with common monogenic Alzheimer鈥檚 disease-related mutations, helping improve the translatability of in vitro research. 

Start effortlessly with our library of applications and protocols

Tri-culture of ioGlutamatergic Neurons, ioGABAergic Neurons and astrocytes protocol (2)

Study functional neural networks

Modelling of cellular interactions by culturing excitatory and inhibitory neurons with astrocytes.

Tri-culture protocol
Website Resources Cards_Quantifying C5a-mediated chemotaxis in precision reprogrammed hiPSC-derived ioMicroglia

Model disease progression

Learn how to study the role of C5a and other proteins in driving neuroinflammation.

Access the application note
ioMicroglia cytokine release

Analyse cytokine profiles

Investigate potential therapeutic compounds that can modulate microglial activation by measuring changes in cytokine secretion.

Stimulation for cytokine release protocol

Validated through real-world applications and results

Disease related phenotye - Data

Study disease-related phenotypes

Quantification of 饾浗-amyloid peptide secretion in an Alzheimer鈥檚 disease model toolkit with a genetically matched control.

V-PLEX A饾浗 peptide data
Case study

Building consistent in vitro assays for CNS drug development

Learn how ioMicroglia offered Concept Life Sciences functional cells with low inter-lot variability, ensuring consistent assay performance, facilitating large scale screening studies.

Read the case study
App note - inventia

Scalable 3D models for screening

Find out how Inventia Life Science generated functional 3D neuronal models in 96- and 384-well formats that closely resembled the human brain.

Access the application note
bb-card-image-520-x-360-1-CaseStudy-SpeedingUpResearch (1)

Quickly identify disease risk factors

Discover how Professor Srivastava, King's College London, generated publishable data in just 12 weeks.

Read the case study

Easily conduct your own Alzheimer's disease-related gene knockouts, activation and interference experiments with CRISPR-Ready ioCells 

CRISPR-Ready ioCells offer a fast and simple toolkit for gene editing in human iPSC-derived neurons and glia. Engineered to constitutively express Cas9 nuclease or dCas9 variants, these cells enable scientists to easily knockout, activate or interfere with their gene of interest in physiologically relevant cells in a matter of days. 

Discover CRISPR-Ready ioCells
ioGlutamatergic-Neurons-CRISPR-Ready-Hero-Image square

Don鈥檛 see what you鈥檙e looking for? Partner with us to generate custom ioDisease Model Cells to study Alzheimer's disease

Access our platform to generate custom ioCells to precisely answer your drug discovery and disease research questions.

Learn more about our custom ioDisease Model Cells offering
91探花 lab scientist with sample

Related pages

Browse product portfolio Purchase our range of human iPSC-derived cells for research and drug discovery
Resources Explore our latest scientific insights, webinars, blogs and videos
Our platform Discover the cell identity coding platform behind our ioCells portfolio